Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders

Annals of Neurology

Volumn 70, Issue 4, 2011, Pages 532-540

  Jucker, Mathias ^a,b   Walker, Lary C ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN EXTRACT; COPPER ZINC SUPEROXIDE DISMUTASE; HUNTINGTIN; PRION PROTEIN; PROTEINASE K; TAR DNA BINDING PROTEIN; TAU PROTEIN; DNA BINDING PROTEIN; PROTEIN; PROTEIN TDP-43;

ALZHEIMER DISEASE; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BETA SHEET; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN REGION; CELL PROLIFERATION; CHRONIC WASTING DISEASE; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; IDIOPATHIC DISEASE; MICROSCOPY; NEUROFIBRILLARY TANGLE; NONHUMAN; PREDICTION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FOLDING; SCRAPIE; SENILE PLAQUE; TRANSMISSIBLE MINK ENCEPHALOPATHY; VASCULAR AMYLOIDOSIS; ANIMAL; CHEMISTRY; METABOLISM; PATHOLOGY; PRION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DNA-BINDING PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; PRIONS; PROTEINS; TAU PROTEINS;

EID: 80054024011     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22615     Document Type: Article

References (110)

1. Brown P, Salazar AM, Gibbs CJ Jr, Gajdusek DC. Alzheimer's disease and transmissible virus dementia (Creutzfeldt-Jakob disease). Ann N Y Acad Sci 1982;396:131-143.
2. Prusiner SB. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 1984;310:661-663. (Pubitemid 14194391)
3. Gajdusek DC. Spontaneous generation of infectious nucleating amyloids in the transmissible and nontransmissible cerebral amyloidoses. Mol Neurobiol 1994;8:1-13.
4. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second century. Sci Transl Med 2011;3:77sr1.
5. Jucker M, Beyreuther K, Haass C, et al, eds. Alzheimer: 100 years and beyond. New York, NY: Springer, 2006.
6. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982;56:343-356. (Pubitemid 12002356)
7. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682-1687. (Pubitemid 18265029)
8. Braak H, Braak E. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356. (Pubitemid 34790756)
10. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006;2006:re1.
11. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036.
12. Powers ET, Morimoto RI, Dillin A, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009;78:959-991.
13. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-b peptide clearance. Sci Transl Med 2011;3:89ra57.
14. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95: 6448-6453.
15. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440: 352-357.
16. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112. (Pubitemid 46432529)
17. Shankar GM, Li S, Mehta TH, et al. Amyloid-βeta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.
18. Jin M, Shepardson N, Yang T, et al. Soluble amyloid betaprotein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011;108:5819-5824.
19. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316: 750-754. (Pubitemid 46717684)
20. Ittner LM, Götz J. Amyloid-βeta and tau-α toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011;12:65-72.
21. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800. (Pubitemid 34663580)
22. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717. (Pubitemid 41208641)
23. Walker LC, Jucker M. Amyloid by default. Nat Neurosci 2011;14: 669-670.
24. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011;121:171-181.
25. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: Potential role in system degenerations, including Alzheimer's disease. Neuroscience 1987;23:389-398. (Pubitemid 18004218)
26. Hardy J. An 'anatomical cascade hypothesis' for Alzheimer's disease. Trends Neurosci 1992;15:200-201.
27. Klunk WE, Mathis CA. The future of amyloid-beta imaging: A tale of radionuclides and tracer proliferation. Curr Opin Neurol 2008; 21:683-687.
28. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-192.
29. Prusiner SB. Shattuck lecture-neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526.
30. Prusiner SB. Prion biology and diseases. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 2004.
31. Brown K, Mastrianni JA. The prion diseases. J Geriatr Psychiatry Neurol 2010;23:277-298.
32. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: The National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513-529. (Pubitemid 24153834)
33. Wadsworth JD, Asante EA, Collinge J. Review: Contribution of transgenic models to understanding human prion disease. Neuropathol Appl Neurobiol 2010;36:576-597.
34. Belay ED, Schonberger LB. The public health impact of prion diseases. Annu Rev Public Health 2005;26:191-212. (Pubitemid 40547381)
35. Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 2007;8: 552-561. (Pubitemid 46985384)
36. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007;318:930-936. (Pubitemid 350098981)
37. Soto C. Prion hypothesis: The end of the controversy? Trends Biochem Sci 2011;36:151-158.
38. Bueler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992;356:577-582.
39. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009;64:783-790.
40. Parchi P, Strammiello R, Giese A, Kretzschmar H. Phenotypic variability of sporadic human prion disease and its molecular basis: Past, present, and future. Acta Neuropathol 2011;121: 91-112.
41. Walker LC, Levine H III, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci 2006;29:438-443. (Pubitemid 44118445)
42. Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 2006;31:150-155. (Pubitemid 43357995)
43. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010;11:155-159.
44. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010;11:301-307.
45. Goedert M, Clavaguera F, Tolnay M. The propagation of prionlike protein inclusions in neurodegenerative diseases. Trends Neurosci 2010;33:317-325.
46. Goudsmit J, Morrow CH, Asher DM, et al. Evidence for and against the transmissibility of Alzheimer disease. Neurology 1980;30:945-950. (Pubitemid 10059245)
47. Baker HF, Ridley RM, Duchen LW, et al. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol 1993;74:441-454. (Pubitemid 23304080)
48. Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 2006;113:1243-1251. (Pubitemid 44291018)
49. Kane MD, Lipinski WJ, Callahan MJ, et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci 2000;20:3606-3611. (Pubitemid 30266223)
50. Walker LC, Callahan MJ, Bian F, et al. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 2002;23:1241-1247. (Pubitemid 34786703)
51. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006;313:1781-1784. (Pubitemid 44454153)
52. Eisele YS, Bolmont T, Heikenwalder M, et al. Induction of cerebral beta-amyloidosis: Intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 2009;106:12926-12931.
53. Watts JC, Giles K, Grillo SK, et al. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A 2011;108:2528-2533.
54. Langer F, Eisele YS, Fritschi S, et al. Soluble Ab seeds are potent inducers of cerebral b-amyloid deposition. J Neurosci 2011;31: 14488-14495.
55. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18:253-266. (Pubitemid 351430402)
56. Eisele YS, Obermüller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010;330:980-982.
57. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science 2004;305:673-676. (Pubitemid 39006757)
58. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010;327: 1132-1135.
59. Petkova AT, Leapman RD, Guo Z, et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005;307:262-265. (Pubitemid 40116242)
60. Nilsson KP, Aslund A, Berg I, et al. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol 2007;2: 553-560. (Pubitemid 350011326)
61. Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2010;119:221-233.
62. Levine H III, Walker LC. Molecular polymorphism of Abeta in Alzheimer's disease. Neurobiol Aging 2010;31:542-548.
63. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909-913.
64. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009;284: 12845-12852.
65. Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 2009;284:3546-3551.
66. Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011;286:15317-15331.
67. Crowther RA, Goedert M. Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol 2000;130:271-279.
68. Wegmann S, Jung YJ, Chinnathambi S, et al. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem 2010;285:27302-27313.
69. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-1495. (Pubitemid 32807681)
70. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP Tau transgenic mice. Am J Pathol 2007;171:2012-2020.
71. Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103:1953-1958. (Pubitemid 43228799)
72. Miller Y, Ma B, Nussinov R. Synergistic interactions between repeats in tau protein and Abeta amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry 2011;50:5172-5181.
73. Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995;14:879-888.
74. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337-351. (Pubitemid 46161268)
75. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, et al. GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol 2010;223:322-325.
76. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211. (Pubitemid 36007810)
77. Braak H, Del Tredici K. Pathophysiology of sporadic Parkinson's disease [in German]. Fortschr Neurol Psychiatr 2010;78(suppl 1): S2-S4.
78. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503. (Pubitemid 351655211)
79. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506. (Pubitemid 351655212)
80. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alphasynuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
81. Hansen C, Angot E, Bergstrom AL, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121:715-725.
82. Kordower JH, Dodiya HB, Kordower AM, et al. Transfer of hostderived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011;43:552-557.
83. Chia R, Tattum MH, Jones S, et al. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One 2010;5:e10627.
84. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011;108:3548-3553.
85. Furukawa Y, Kaneko K, Watanabe S, et al. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 2011;286:18664-18672.
86. Ren PH, Lauckner JE, Kachirskaia I, et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009;11:219-225.
87. Lee SJ, Desplats P, Sigurdson C, et al. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010;6:702-706.
88. Luk KC, Song C, O'Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009;106: 20051-20056.
89. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25: 6016-6024. (Pubitemid 40911433)
90. Urushitani M, Sik A, Sakurai T, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006;9:108-118. (Pubitemid 43011916)
91. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol 2011;10:230-240.
92. Hu X, Crick SL, Bu G, et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A 2009;106:20324-20329.
93. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 2006;103:11172-11177. (Pubitemid 44156491)
94. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177-1187.
95. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 2011; 69:203-213.
96. Lansbury PT Jr. Structural neurology: Are seeds at the root of neuronal degeneration? Neuron 1997;19:1151-1154. (Pubitemid 28030534)
97. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005;437:257-261. (Pubitemid 41294488)
98. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284-295.
99. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72. (Pubitemid 43233790)
100. Yagi H, Kusaka E, Hongo K, et al. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: Implications for the mechanism of transmissible conformational diseases. J Biol Chem 2005;280:38609-38616. (Pubitemid 43853762)
101. Westermark GT, Westermark P. Prion-like aggregates: Infectious agents in human disease. Trends Mol Med 2010;16:501-507.
102. Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 2011; 31:7604-7618.
103. Cherny I, Gazit E. Amyloids: Not only pathological agents but also ordered nanomaterials. Angew Chem Int Ed Engl 2008;47: 4062-4069.
104. Knowles TPJ, Buehler MJ. Nanomechanics of functional and pathological amyloid materials. Nat Nanotechnol 2011;6: 469-479.
105. Meyer-Luehmann M, Stalder M, Herzig MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003;6:370-377. (Pubitemid 36373982)
106. Ward HJ, Everington D, Croes EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: A case-control study using community controls. Neurology 2002;59:543-548. (Pubitemid 34919987)
107. Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 2005;6:435-450. (Pubitemid 40733889)
108. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T. Prions of fungi: Inherited structures and biological roles. Nat Rev Microbiol 2007;5:611-618. (Pubitemid 47074116)
109. Tuite MF, Serio TR. The prion hypothesis: From biological anomaly to basic regulatory mechanism. Nat Rev Mol Cell Biol 2010; 11:823-833.
110. Norrby E. Prions and protein-folding diseases. J Intern Med 2011;270:1-14.